RU2008143202A - Композиции, способы и наборы с использованием аденозина и инозина в комбинации для диагностики и лечения - Google Patents

Композиции, способы и наборы с использованием аденозина и инозина в комбинации для диагностики и лечения Download PDF

Info

Publication number
RU2008143202A
RU2008143202A RU2008143202/15A RU2008143202A RU2008143202A RU 2008143202 A RU2008143202 A RU 2008143202A RU 2008143202/15 A RU2008143202/15 A RU 2008143202/15A RU 2008143202 A RU2008143202 A RU 2008143202A RU 2008143202 A RU2008143202 A RU 2008143202A
Authority
RU
Russia
Prior art keywords
inosine
adenosine
ratio
mcg
optionally
Prior art date
Application number
RU2008143202/15A
Other languages
English (en)
Russian (ru)
Inventor
Филипп ГОРНИ (FR)
Филипп ГОРНИ
Original Assignee
Аденобио Н.В. (Nl)
Аденобио Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аденобио Н.В. (Nl), Аденобио Н.В. filed Critical Аденобио Н.В. (Nl)
Publication of RU2008143202A publication Critical patent/RU2008143202A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2008143202/15A 2006-03-31 2007-03-30 Композиции, способы и наборы с использованием аденозина и инозина в комбинации для диагностики и лечения RU2008143202A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78777106P 2006-03-31 2006-03-31
US60/787,771 2006-03-31

Publications (1)

Publication Number Publication Date
RU2008143202A true RU2008143202A (ru) 2010-05-10

Family

ID=38197939

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008143202/15A RU2008143202A (ru) 2006-03-31 2007-03-30 Композиции, способы и наборы с использованием аденозина и инозина в комбинации для диагностики и лечения

Country Status (12)

Country Link
US (1) US20080056993A1 (https=)
EP (1) EP2004139A1 (https=)
JP (1) JP2009531367A (https=)
KR (1) KR20090010176A (https=)
CN (1) CN101453984A (https=)
AU (1) AU2007234006A1 (https=)
CA (1) CA2647770A1 (https=)
IL (1) IL194423A0 (https=)
NO (1) NO20084599L (https=)
RU (1) RU2008143202A (https=)
WO (1) WO2007112986A1 (https=)
ZA (1) ZA200808368B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
HU227743B1 (en) 2011-07-22 2012-02-28 Debreceni Egyetem Eardrop composition and process for producing this
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231086A (en) * 1985-09-24 1993-07-27 Item Development Aktiebolag Continuous administration adenosine to increase myocardial blood flow
DE3701497A1 (de) * 1987-01-20 1988-07-28 Frankhof Wolfgang Arzneimittel, enthaltend lokalanaesthetika und nukleoside sowie dessen verwendung zur behandlung von muskelverletzungen
US5070877A (en) * 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
US5187162A (en) * 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US6180616B1 (en) * 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
WO1994023723A1 (en) * 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
SE9301324D0 (sv) * 1993-04-21 1993-04-21 Item Development Ab New method of treatment
US6342484B1 (en) * 1993-06-30 2002-01-29 Board Of Regents, The University Of Texas Systems Method and compositions for promotion of wound treatment
US5852000A (en) * 1993-08-25 1998-12-22 Otsuka Pharmaceutical Factory, Inc. Cardiac rehabilitation agent
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
SE9401499D0 (sv) * 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
US5629298A (en) * 1995-03-13 1997-05-13 University Of Massachusetts Medical Center Adenosine as a positive inotrop in the compromised heart
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
AU2603197A (en) * 1996-04-10 1997-10-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
US5873366A (en) * 1996-11-07 1999-02-23 Chim; Nicholas Method for transmyocardial revascularization
US6211165B1 (en) * 1997-05-09 2001-04-03 The Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
AU1363699A (en) * 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
EP1168912B1 (en) * 1999-03-23 2007-05-09 Hibernation Therapeutics Limited Organ arrest, protection and preservation
US6103702A (en) * 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US6492103B1 (en) * 2000-01-31 2002-12-10 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
US6566371B2 (en) * 2000-04-28 2003-05-20 University Of Pittsburgh Intraperitoneal administration of adenosine for the treatment of prevention of gastrointestinal of systemic diseases
US6599283B1 (en) * 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
EP1575562B1 (en) * 2002-11-26 2016-10-05 Seacoast Neurosciene, Inc. Buoyant polymer particles delivering therapeutic agents

Also Published As

Publication number Publication date
IL194423A0 (en) 2009-08-03
CN101453984A (zh) 2009-06-10
KR20090010176A (ko) 2009-01-29
US20080056993A1 (en) 2008-03-06
CA2647770A1 (en) 2007-10-11
ZA200808368B (en) 2009-12-30
JP2009531367A (ja) 2009-09-03
NO20084599L (no) 2008-10-30
EP2004139A1 (en) 2008-12-24
AU2007234006A1 (en) 2007-10-11
WO2007112986A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
Biaggioni et al. Cardiovascular and respiratory effects of adenosine in conscious man. Evidence for chemoreceptor activation.
Yang et al. Postconditioning’s protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3–kinase and guanylyl cyclase activation
JP4980530B2 (ja) アデノシン受容体アゴニストまたはアンタゴニストを含む製薬組成物
CA2708264C (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
EA001379B1 (ru) Способы лечения неврологического расстройства у животного, способы стимуляции и активации роста поврежденных периферических нервов, способ активации регенерации и роста нейронов и способ предотвращения нейродегенерации у животного
RU2009106862A (ru) Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
EP0735888A1 (en) Purine compositions and methods for administration
CA2655310A1 (en) Use of a2a adenosine receptor agonists in the treatment of ischemia
JP2010515081A5 (https=)
Chester et al. Interaction between thromboxane A2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries.
JP5892565B2 (ja) 増殖性疾患を治療するためのサパシタビンの使用
AU2005295437B2 (en) Use of A2A adenosine receptor agonists
US20030032618A1 (en) Pharmaceutical combinations
RU2008143202A (ru) Композиции, способы и наборы с использованием аденозина и инозина в комбинации для диагностики и лечения
Smits et al. Dose‐dependent inhibition of the hemodynamic response to dipyridamole by caffeine
JP2009531367A5 (https=)
Marichal-Cancino et al. Intrathecal dihydroergotamine inhibits capsaicin-induced vasodilatation in the canine external carotid circulation via GR127935-and rauwolscine-sensitive receptors
CN101856498A (zh) 一种抗感染性休克的药物组合物及其应用
US8791079B2 (en) Methods for treating heart failure by inhibiting the mitochondrial sodium-calcium exchanger (mNCE)
Sidi et al. Cardiovascular effects of a non-xanthine-selective antagonist of the A1 adenosine receptor in the anaesthetised pig: pharmacological and therapeutic implications
CHIBA et al. Vascular responsiveness of isolated, perfused basilar arteries in dogs and monkeys
US20170106011A1 (en) Methods of treating traumatic brain injury and sequelae
Crean et al. Fentanyl-oxygen versus fentanyl-N2O/oxygen anaesthesia in children undergoing cardiac surgery
Saito et al. Enhancement of the vasodepressor response to adenosine by nicorandil in rats: comparison with cromakalim
Zambotti et al. Zopiclone potentiates the antinociceptive effect of morphine in rats

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110829